<DOC>
	<DOCNO>NCT00647244</DOCNO>
	<brief_summary>To evaluate efficacy safety switch Retrovir Tenofovir Abacavir HIV-infected patient</brief_summary>
	<brief_title>Efficacy Safety Switching From Retrovir Tenofovir Abacavir HIV-infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<criteria>HIVinfection undetectable viral load Antiretroviral treatment include Retrovir three month If fertile female : Negative pregnancy test use safe contraception Negative HBsantigen titer Prior treatment abacavir tenofovir Resistance towards abacavir tenofovir Tissue type HLAB5701 Renal disease Diabetes Mellitus Osteoporosis Pregnant lactate subject Intravenous drug abuse Hypersensitivity towards drug active ingredient use ALAT &gt; 5 time upper normal level Current alcohol substance abuse judge Investigator potentially interfere subject compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Tenofovir</keyword>
	<keyword>Abacavir</keyword>
	<keyword>Antiretroviral therapy</keyword>
	<keyword>HIV</keyword>
	<keyword>Nucleoside analogue reverse transcriptase inhibitor</keyword>
</DOC>